Education
About Us
Working with TipRanks
Follow Us
Idorsia Ltd (CH:IDIA)
:IDIA
IDIA Stock Chart & Stats
CHF4.00
-CHF0.05(-3.98%)
At close: 4:00 PM EST
CHF4.00
-CHF0.05(-3.98%)
Day’s Range― - ―
52-Week RangeCHF0.70 - CHF4.85
Previous CloseN/A
Volume178.76K
Average Volume (3M)2.48M
Market Cap
CHF901.65M
Enterprise ValueCHF2.00B
Total Cash (Recent Filing)CHF71.20M
Total Debt (Recent Filing)CHF1.26B
Price to Earnings (P/E)―
Beta2.20
Next Earnings
Feb 26, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding251,506,700
10 Day Avg. Volume2,649,008
30 Day Avg. Volume2,478,790
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-0.12
Price to Sales (P/S)1.33
P/FCF Ratio-0.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF5.25Price Target Upside31.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Differentiation And Partner AppealAprocitentan's Canadian approval and strong blood pressure and kidney protection data position the drug as a differentiated therapy and increase its attractiveness to potential North American commercial partners.
Commercial Expansion And Near‑term CashExclusive license and supply agreement for daridorexant in Brazil opens Latin American commercialization, with milestone payments, supply revenue, and royalties that strengthen near‑term cash position.
Regulatory PathwayRegulatory‑agreed Phase 3 design for lucerastat targets kidney damage and uses kidney biopsy as primary evidence, providing a clear clinical framework to seek approval for patients regardless of mutation type.
Bears Say
Clinical Trial Execution RiskRegulatory approval depends heavily on demonstrating meaningful kidney improvement in clinical studies, creating substantial execution and late‑stage trial risk for key programs.
Dependence On Approvals And PartnersProgress and commercialization plans rely on successful regulatory approvals and strategic partner support, making outcomes vulnerable if approvals or partnerships fail to materialize.
Financial Exposure To Late‑stage FailuresFailure of late‑stage drug candidates would jeopardize anticipated milestone and partnership revenue, increasing the likelihood of additional financing needs or strategic reprioritization.
IDIA FAQ
What was Idorsia Ltd’s price range in the past 12 months?
Idorsia Ltd lowest stock price was CHF0.69 and its highest was CHF4.85 in the past 12 months.
What is Idorsia Ltd’s market cap?
Idorsia Ltd’s market cap is CHF901.65M.
When is Idorsia Ltd’s upcoming earnings report date?
Idorsia Ltd’s upcoming earnings report date is Feb 26, 2026 which is in 16 days.
How were Idorsia Ltd’s earnings last quarter?
Idorsia Ltd released its earnings results on Oct 30, 2025. The company reported -CHF0.275 earnings per share for the quarter, missing the consensus estimate of -CHF0.22 by -CHF0.055.
Is Idorsia Ltd overvalued?
According to Wall Street analysts Idorsia Ltd’s price is currently Undervalued.
Does Idorsia Ltd pay dividends?
Idorsia Ltd pays a Notavailable dividend of CHF11.841 which represents an annual dividend yield of N/A. See more information on Idorsia Ltd dividends here
What is Idorsia Ltd’s EPS estimate?
Idorsia Ltd’s EPS estimate is -0.2.
How many shares outstanding does Idorsia Ltd have?
Idorsia Ltd has 251,506,700 shares outstanding.
What happened to Idorsia Ltd’s price movement after its last earnings report?
Idorsia Ltd reported an EPS of -CHF0.275 in its last earnings report, missing expectations of -CHF0.22. Following the earnings report the stock price went down -1.63%.
Which hedge fund is a major shareholder of Idorsia Ltd?
Currently, no hedge funds are holding shares in CH:IDIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
IDIA Stock 12 Month Forecast
Average Price Target
CHF5.25
▲(31.25% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Kuros Biosciences
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
Options Prices
Currently, No data available
---